Fasciola gigantica Fatty Acid Binding Protein (FABP) as a Prophylactic Agent against Schistosoma mansoni Infection in CD1 Mice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although schistosomicidal drugs and other control measures exist, the advent of an efficacious vaccine remains the most potentially powerful means for controlling this disease. In this study, native fatty acid binding protein (FABP) from Fasciola gigantica was purified from the adult worm’s crude extract by saturation with ammonium sulphate followed by separation on DEAE-Sephadex A-50 anion exchange chromatography and gel filtration using Sephacryl HR-100, respectively. CD1 mice were immunized with the purified, native F. gigantica FABP in Freund’s adjuvant and challenged subcutaneously with 120 Schistosoma mansoni cercariae. Immunization of CD1 mice with F. gigantica FABP has induced heterologous protection against S. mansoni, evidenced by the significant reduction in mean worm burden (72.3%), liver and intestinal egg counts (81.3% and 80.8%, respectively), and hepatic granuloma counts (42%). Also, it elicited mixed IgG1/IgG2b immune responses with predominant IgG1 isotype, suggesting that native F. gigantica FABP is mediated by a mixed Th1/Th2 response. However, it failed to induce any significant differences in the oogram pattern or in the mean granuloma diameter. This indicated that native F. gigantica FABP could be a promising vaccine candidate against S. mansoni infection.
Abstract
Although schistosomicidal drugs and other control measures exist, the advent of an efficacious vaccine remains the most potentially powerful means for controlling this disease. In this study, native fatty acid binding protein (FABP) from Fasciola gigantica was purified from the adult worm’s crude extract by saturation with ammonium sulphate followed by separation on DEAE-Sephadex A-50 anion exchange chromatography and gel filtration using Sephacryl HR-100, respectively. CD1 mice were immunized with the purified, native F. gigantica FABP in Freund’s adjuvant and challenged subcutaneously with 120 Schistosoma mansoni cercariae. Immunization of CD1 mice with F. gigantica FABP has induced heterologous protection against S. mansoni, evidenced by the significant reduction in mean worm burden (72.3%), liver and intestinal egg counts (81.3% and 80.8%, respectively), and hepatic granuloma counts (42%). Also, it elicited mixed IgG1/IgG2b immune responses with predominant IgG1 isotype, suggesting that native F. gigantica FABP is mediated by a mixed Th1/Th2 response. However, it failed to induce any significant differences in the oogram pattern or in the mean granuloma diameter. This indicated that native F. gigantica FABP could be a promising vaccine candidate against S. mansoni infection.
참고문헌 (34)
- King CH, "Toward the elimination of schistosomiasis", N Engl J Med, 360, pp.106~109 (2009)
- Steinmann P, "Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk", Lancet Infect Dis, 6, pp.411~425 (2006)
- van der Werf MJ, "Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa", Acta Trop, 86, pp.125~139 (2003)
- McManus DP, "Current status of vaccines for schistosomiasis", Clin Microbiol Rev, 21, pp.225~242 (2008)
- Capron A, "Schistosomes: the road from host-parasite interactions to vaccines in clinical trials", Trends Parasitol, 21, pp.143~149 (2005)
- Wilson RA, "Schistosome vaccines: a critical appraisal", Mem Inst Oswaldo Cruz, 101, pp.S13~S20 (2006)
- Hillyer GV, "Fasciola antigens as vaccines against fascioliasis and schistosomiasis", J Helminthol, 79, pp.241~247 (2005)
- Abán JL, "A fatty acid binding protein from Fasciola hepatica induced protection in C57", BL mice from challenge infection with Schistosoma bovis, 1999, pp.83, 107~121
- Sirisriro A, "Production and characterization of a monoclonal antibody against recombinant fatty acid binding protein of Fasciola gigantica", Vet Parasitol, 105, pp.119~129 (2002)
- Nessim NG, "Effect of the broad spectrum anthelmintic drug flubendazole upon Schistosoma mansoni experimentally infected mice", Arzneimittelforschung, 50, pp.1129~1133 (2000)
- Timanova A, "Ascaridia galli fatty acid-binding protein, a member of the nematode polyprotein allergens family", Eur J Biochem, 261, pp.569~576 (1999)
- Laemmli UK, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4", Nature, 227, pp.680~685 (1970)
- Duvall RH, "An improved perfusion technique for recovering adult schistosomes from laboratory animals", Am J Trop Med Hyg, 16, pp.483~486 (1967)
- Cheever AW, "Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues", Bull World Health Organ, 39, pp.328~331 (1968)
- Pellegrino J, "New approach to the screening of drugs in experimental Schistosomiasis mansoni in mice", Am J Trop Med Hyg, 11, pp.201~215 (1962)
- Engvall E, "Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G", Immunochemistry, 8, pp.871~874 (1971)
- von Lichtenberg, "Host response to eggs of S. mansoni. I. Granuloma formation in the unsensitized laboratory mouse", Am J Pathol, 41, pp.711~731 (1962)
- Cherfas J, "New hope for vaccine against schistosomiasis", Science, 251, pp.630~631 (1991)
- McManus DP, "A vaccine against Asian schistosomiasis: the story unfolds", Int J Parasitol, 30, pp.265~271 (2000)
- Hillyer GV, "Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein", Mem Inst Oswaldo Cruz, 90, pp.249~253 (1995)
- Janecharut T, "Investigation on immunity induced by Schistosoma spindale against S. mekongi in experimental mice", Southeast Asian J Trop Med Public Health, 19, pp.123~129 (1988)
- Agnew AM, "Specific cross-protection between Schistosoma bovis and S. haematobium induced by highly irradiated infections in mice", Parasite Immunol, 11, pp.341~349 (1989)
- Dean DA, "Homologous and heterologous protective immunity to Egyptian strains of Schistosoma mansoni and S. haematobium induced by ultraviolet- irradiated cercariae", Parasite Immunol, 18, pp.403~410 (1996)
- Rabia I, "Intraperitoneal injection of Echinostome antigens confers resistance to schistosomal infection in murine model", New Egypt J Med, 36, pp.25~31 (2007)
- Siles-Lucas M, "The Schistosoma bovis Sb14-3-3zeta recombinant protein cross-protects against Schistosoma mansoni in BALB", c mice, 2007, pp.25, 7217~7223
- Hamed MA, "Excretory-secretory product of Fasciola hepatica worm protects against Schistosoma mansoni infection in mice", Indian J Exp Biol, 44, pp.554~561 (2006)
- Snapper CM, "Towards a comprehensive view of immunoglobulin class switching", Immunol Today, 14, pp.15~17 (1993)
- Pfeifhofer C, "Defective IgG2a", 2b class switching in PKC alpha-, J Immunol, pp.2006, 176[DOI]
- Nascimento E, "Protective immunity of single and multi-antigen DNA vaccines against schistosomiasis", Mem Inst Oswaldo Cruz, 97, pp.S105~S109 (2002)
- Dupré, "Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment", J Infect Dis, 180, pp.454~463 (1999)
- Ramos HR, "A genetic fusion between Sm14 and CTB does not reduce Schistosoma mansoni worm burden on intranasally immunized BALB", c mice, 2010, pp.1, 111~
- Pearce EJ, "Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen", Proc Natl Acad Sci U S A, 85, pp.5678~5682 (1988)
- Cardoso FC, "Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection", PLoS Negl Trop Dis, 2, pp.e308~ (2008)
- Siddiqui AA, "Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin- 2 and interleukin-12 in a DNA vaccine formulation", Vaccine, 21, pp.2882~2889 (2003)